Company Description
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company’s products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body.
BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania.
The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011.
BioRestorative Therapies, Inc. is headquartered in Melville, New York.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Lance Alstodt |
Contact Details
Address: 40 Marcus Drive, Suite 1 Melville, New York 11747 United States | |
| Phone | 631 760 8100 |
| Website | biorestorative.com |
Stock Details
| Ticker Symbol | BRTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1505497 |
| CUSIP Number | 090655606 |
| ISIN Number | US0906556065 |
| Employer ID | 30-1341024 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Lance Alstodt | Chairman of the Board, President and Chief Executive Officer |
| Robert Eugene Kristal | Chief Financial Officer |
| Francisco J. Silva | Vice President of Research and Development, Secretary and Director |
| Stephen Kilmer | Investor Relations Officer |
| Crystal Romano | Head of Global Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G | Filing |
| Feb 13, 2026 | 424B4 | Prospectus |
| Feb 11, 2026 | EFFECT | Notice of Effectiveness |
| Feb 10, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 19, 2025 | DRS | [Cover] Draft Registration Statement |
| Dec 19, 2025 | SCHEDULE 13G/A | Filing |